Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRES	CRIBI	ER		PATIENT:			
Name	:			Name:			
Ward:				NHI:			
Dexr	azox	ane					
Prere	INITIATION Prerequisites (tick boxes where appropriate) Prescribed by, or recommended by a medical oncologist, paediatric oncologist, haematologist or paediatric haematologist, or in accordance wit a protocol or guideline that has been endorsed by the Health NZ Hospital.						
and	and and and	C	Patient is to receive treatment with high dose anthracycline given with curative intent Based on current treatment plan, patient's cumulative lifetime dose of anthracycline will exceed 250mg/m2 doxorubicin equivalent or greater				
		C	Dexrazoxane to be administered only whilst on anthracycline	treatment			
			O Treatment to be used as a cardioprotectant for a child of	or young adult			
		or	O Treatment to be used as a cardioprotectant for secondary	ary malignancy			

C:	D-1	
Signed.	Date:	
Oigilica.	 Daic.	